From Wikipedia, the free encyclopedia
|Chemical and physical data|
|Molar mass||199.64 g/mol|
Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|